India, Feb. 24 -- image credit- freepik

Eris Lifesciences has announced a strategic partnership with Natco Pharma for the commercialisation ofSemaglutidein India, reinforcing Eris's commitment to expanding its leadership in the fast-growing diabetes and metabolic care segment.

Semaglutide, a GLP-1 receptor agonist, has emerged globally as a transformative therapy in the management of Type 2 diabetes and chronic weight management driven by robust clinical outcomes in glycemic control and weight reduction. With India witnessing a rapidly growing diabetic population and increasing awareness around obesity management, GLP-1 therapies represent a high-growth opportunity within the metabolic segment.

Eris has built a strong and scalable pres...